260 related articles for article (PubMed ID: 8185340)
21. Serum CA 125 levels in patients with endometriosis: changes in CA 125 levels during menstruation.
Masahashi T; Matsuzawa K; Ohsawa M; Narita O; Asai T; Ishihara M
Obstet Gynecol; 1988 Sep; 72(3 Pt 1):328-31. PubMed ID: 3165507
[TBL] [Abstract][Full Text] [Related]
22. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
23. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous measurement of CA 125, CA 19-9, tissue polypeptide antigen, and immunosuppressive acidic protein to predict recurrence of ovarian cancer.
Kamiya N; Mizuno K; Kawai M; Kano T; Furuhashi Y; Tomoda Y
Obstet Gynecol; 1990 Sep; 76(3 Pt 1):417-21. PubMed ID: 2381619
[TBL] [Abstract][Full Text] [Related]
25. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer.
Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P
Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561
[TBL] [Abstract][Full Text] [Related]
26. [Application of monoclonal antibody OC 125 in gynecological oncology].
Wu AR; Wang EY; Wang XX; Jia XH; Li L
Zhonghua Zhong Liu Za Zhi; 1988 Mar; 10(2):132-6. PubMed ID: 3208653
[TBL] [Abstract][Full Text] [Related]
27. [Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer].
Kimura E; Murae M; Koga R; Odawara Y; Nakabayashi Y; Yokoyama K; Nakata H; Totake T; Ochiai K; Yasuda M
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Nov; 36(11):2121-8. PubMed ID: 6595320
[TBL] [Abstract][Full Text] [Related]
28. Tumor-associated mucin-type glycoprotein (CA54/61) defined by two monoclonal antibodies (MA54 and MA61) in ovarian cancers.
Nozawa S; Yajima M; Kojima K; Iizuka R; Mochizuki H; Sugawara T; Iwamori M; Nagai Y
Cancer Res; 1989 Jan; 49(2):493-8. PubMed ID: 2910468
[TBL] [Abstract][Full Text] [Related]
29. [CA 125 (cancer antigen 125), a new tumor associated antigen recognized by monoclonal antibody].
Suzuki H; Teshima K; Noda K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2719-23. PubMed ID: 6594978
[TBL] [Abstract][Full Text] [Related]
30. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
31. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3.
Jacobs IJ; Oram DH; Bast RC
Obstet Gynecol; 1992 Sep; 80(3 Pt 1):396-9. PubMed ID: 1495694
[TBL] [Abstract][Full Text] [Related]
32. [Regulation of ceruloplasmin activity in oncogynecological diseases].
Gusarova IuN; Stepanova EV; Landesman EO; Koroleva OV; Vavilova TP; Makarov OV; Kosetskiĭ VN
Vopr Med Khim; 2002; 48(4):388-93. PubMed ID: 12506616
[TBL] [Abstract][Full Text] [Related]
33. [Clinical evaluation of serum CA-50 and CA 19-9 in gynecological tumors].
Suzuki M; Ohwada M; Tamada T; Sakurabayashi I; Kawai T
Rinsho Byori; 1989 Jul; 37(7):784-8. PubMed ID: 2558243
[TBL] [Abstract][Full Text] [Related]
34. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
35. [A study of preclinical and clinical usefulness of new tumor markers of ovarian carcinoma, CA 54/61 and CA 602. 1. Evaluation of the diagnostic accuracy of CA 54/61, a study of the normal range of its values and its correlation with other tumor markers].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hasimoto M
Gan To Kagaku Ryoho; 1992 Jun; 19(6):827-35. PubMed ID: 1605661
[TBL] [Abstract][Full Text] [Related]
36. [Significance of CA 125 antigen levels in patients with ovarian cancer].
Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
[TBL] [Abstract][Full Text] [Related]
37. Saliva and serum CA 125 assays for detecting malignant ovarian tumors.
Chen DX; Schwartz PE; Li FQ
Obstet Gynecol; 1990 Apr; 75(4):701-4. PubMed ID: 2179784
[TBL] [Abstract][Full Text] [Related]
38. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].
Negishi Y; Furuno K; Sano Y; Hirata T; Utsunomiya A; Nakajima H; Okabe K; Shimizu K; Akiya K; Fujiwara Y
Gan No Rinsho; 1985 May; 31(6 Suppl):655-63. PubMed ID: 2993692
[TBL] [Abstract][Full Text] [Related]
39. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
[TBL] [Abstract][Full Text] [Related]
40. [Studies on the clinical significance of type III procollagen peptide in sera as a tumor marker in patients with ovarian tumors].
Mori T; Itoh E
Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):974-89. PubMed ID: 2778385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
